Table 1.

Non-susceptibility to antimicrobials in relation to CC

CC	Total no.	Patient sex (%)			Age (years) (%)					Onset (%)			Non-susceptibility (%)									β-Lactamase (%)
		N/R	female	male	N/R	0–19	20–49	50–69	70+	N/R	≤48 h	>48 h	AMX	AMC	TZP	CTXa	CAZ	CIP	GEN	TGCa	IPM	CTX-M otherb	CTX-M-1	CTX-M-9	ESBL, non-CTX-M	non-ESBL
73	449	0.2	59.5	40.3	0.0	3.6	12.5	20.7	63.3	1.3	64.4	34.3	55.9	27.8	9.1	1.5	1.8	1.3	1.6	0.2	0.0	0.0	0.0	0.0	1.1	98.9
131	302	0.3	42.7	57.0	0.7	3.0	6.6	25.8	63.9	0.0	50.0	50.0	83.4	59.3	22.2	35.0	29.5	64.2	20.2	0.0	0.0	0.3	32.5	0.3	1.0	65.9
95	245	0.0	63.7	36.3	0.4	9.4	13.5	23.7	53.1	0.8	64.5	34.7	45.3	13.9	2.9	0.0	0.0	0.4	2.4	0.0	0.0	0.0	0.0	0.0	0.0	100
69	149	0.0	72.5	27.5	0.0	2.7	18.1	23.5	55.7	0.7	65.8	33.6	81.9	32.2	10.1	1.4	2.0	6.7	4.0	0.7	0.0	0.0	0.7	0.0	0.0	99.3
12	119	0.0	49.6	50.4	0.8	3.4	11.8	22.7	61.3	0.0	68.9	31.1	71.4	28.6	7.6	1.8	5.0	0.8	3.4	0.0	0.0	0.0	0.8	0.0	1.7	97.5
Otherc	902	0.2	50.4	49.3	0.4	4.5	11.2	27.3	56.5	1.1	57.0	41.9	60.9	27.7	9.3	5.3	5.3	15.2	6.4	0.1	0.2	0.2	2.2	0.1	1.0	96.5
Total	2166	0.2	54.2	45.6	0.4	4.5	11.6	24.8	58.8	0.9	59.6	39.5	63.3	30.9	10.3	7.9	7.1	16.1	6.6	0.1	0.1	0.1	5.5	0.1	0.9	93.4

Onset ≤48 h considered as community onset and onset >48 h considered as hospital onset.

Values shaded grey are significantly different (P ≤ 0.0001) compared with the baseline CC73 group.

Values in bold are significant (P ≤ 0.05) compared with the baseline CC73 group.

N/R, not reported; AMX, amoxicillin; AMC, amoxicillin/clavulanate; TZP, piperacillin/tazobactam; CTX, cefotaxime; CAZ, ceftazidime; CIP, ciprofloxacin; GEN, gentamicin; TGC, tigecycline; IPM, imipenem.

^aCefotaxime and tigecycline were tested in 2002–10 only.

^b‘CTX-M other’ indicates an unidentified CTX-M group.

^c‘Other’ CCs includes 902 isolates representing 443 STs, with no more than 65 isolates belonging to any CC.